Novabridge Biosciences current report, Q3 FY2021

Filing Overview

This Form 6-K was filed by I-MAB, a foreign private issuer, for the month of July 2021. The filing date was July 30, 2021, and the SEC commission file number is 001-39173. The filing indicates that I-MAB files annual reports on Form 20-F.

Business Context and Reporting Period

The filing identifies I-MAB’s principal executive offices in Shanghai, China. The submission consists of the Form 6-K cover page and references Exhibit 99.1, described as a press release. The supplied filing text does not include the press release itself.

Financial Metrics

The filing text provided does not report revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.

Material Changes, Outlook, and Risks

The supplied text does not describe material changes versus a prior period, management guidance, outlook, risks, contingencies, or unusual items. Any substantive information may be contained in Exhibit 99.1, which is not included in the provided content.

Key Facts to Verify

  • Confirm that the filing issuer is I-MAB; the supplied metadata identifies a different company name.
  • Review Exhibit 99.1 for the underlying press release and any financial or operational disclosures.
  • Verify whether the July 2021 press release contains guidance, clinical or regulatory updates, financing information, or other material events.